Intuitive Surgical (ISRG) — Q3 FY2026 Earnings Briefing
Fiscal period: Q3 2026 · Report date: October 20, 2026
Executive Summary
- A strong, broad-based quarter: revenue grew 22% YoY to just over $3 billion and non-GAAP EPS rose 25% YoY to $3.00, with adoption expanding across multi-port, single-port, and Ion platforms.
- The tension: management is deliberately trading instrument price for volume, quantifying a per-procedure revenue headwind to unlock high-volume benign procedures.
- Capital demand accelerated on da Vinci 5 momentum and a tiered portfolio aimed at ambulatory surgery centers.
- GAAP results absorbed a sizable no-fault litigation settlement even as the operating beat widened.
- Guidance narrowed upward on procedures and gross margin, with management signaling appetite to reinvest excess margin in 2027 growth.
Highlights and Lowlights
Highlights
- Da Vinci placements rose 28% YoY to 546 systems, with da Vinci 5 and SP together accounting for 65% of global placements.
- Outside-U.S. benign procedures grew 41%, accelerating from 37% in Q2 and 34% in Q1, led by hernia repair and cholecystectomy.
- SP procedures grew 55% YoY on a record 42 placements, with the SP installed base up 42% to 487 systems across 27 countries.
- Da Vinci 5 crossed more than 25% of U.S. procedures, up from 13% a year ago, and continues to run at utilization above the Xi base.
- Cardiac procedures grew 40% and breast surgery 42%, early-stage categories where management sizes the cleared line-of-sight cardiac opportunity at 300,000–400,000 procedures a year.
- U.S. ambulatory momentum built with 18 ASC installations (15 of them XiR), and ASC placements over the last two quarters exceeded almost the prior three years combined.
- Non-GAAP gross margin reached 69.9% — 68.9% excluding a one-time $28 million tariff refund — a 90-basis-point YoY improvement on product cost reductions and overhead leverage.
Lowlights
- U.S. da Vinci procedure growth of 10% was, on the analyst’s framing, the lowest since COVID (analyst-provided); management pointed to a 16% prior-year comparison as the year’s toughest.
- Management quantified its combined pricing actions at a 3%–5% reduction in da Vinci I&A revenue per procedure on a mix-constant basis — China’s policy-driven cut starts in November, the extended-use rollout begins in H1 2027, and full impact arrives only at end-2027.
- GAAP net income fell to $523 million ($1.49 per share) from $704 million ($1.95) a year ago, absorbed by the $450 million no-fault settlement of the third-party remanufacturing class action, which remains subject to court approval next year.
- China remains the hardest market: the charge-code policy change forces significant I&A price reductions beginning in November, capital placements are lower, and the guidance range still assumes tender and competitive pressure.
- Rest-of-world placements fell to 18 systems from 41 a year ago — a line management calls lumpy, but one that dented an otherwise record capital quarter.
- The U.S. demand-policy overhang persists, with management monitoring lower ACA enrollment, changes to Medicaid eligibility, and potential changes to 340B.
- Non-GAAP operating expenses rose 18% YoY on variable compensation, headcount, and prototype spend — and management repeated its willingness to invest the operating-margin cushion rather than defend the peak.
1. Procedure Growth: Broad Internationally, Decelerating in the U.S.
| Procedure metric | Q3 2026 growth |
|---|---|
| Total procedures (da Vinci + Ion) | +15% |
| da Vinci procedures | +14% |
| Ion procedures | +31% |
| U.S. total procedures | +11% |
| U.S. da Vinci | +10% |
| U.S. Ion | +29% |
| OUS total and da Vinci | +20% |
| OUS benign | +41% (from 37% in Q2, 34% in Q1) |
| SP procedures | +55% (U.S. +50%, Korea +40%) |
| Cardiac | +40% |
| Breast | +42% |
The installed base of da Vinci and Ion systems exited the quarter at more than 13,200, up 13%, with average system utilization up 2%. Almost 7,000 customers in more than 70 countries performed da Vinci procedures at a rate of over 10,000 per day.
The U.S. print requires context rather than alarm: management attributed the 10% da Vinci growth in part to the 16% comparison in the prior-year quarter — its most difficult of the year — and noted after-hours procedures and benign gynecology other than hysterectomy continued to lead growth. The durable-growth case rests on breadth of surgeon adoption, benign general surgery expansion, and a growing da Vinci 5 and SP installed base, plus procedures earlier in adoption (emergent general surgery, cardiac, nipple-sparing mastectomy). Internationally, Europe grew 20% led by the UK, Germany, and Italy; Asia grew 19% with India and Taiwan leading — India grew 42% and surpassed 200,000 cumulative procedures — and Japan accelerated for a second straight quarter on early signs of a response to June reimbursement changes. China was roughly in line with the corporate average despite lower recent capital placements. Rest-of-world growth was led by Canada, Australia, and Brazil.
Benign procedures are the strategic center of gravity: they represent over a quarter of international volume and the significant majority of the gap to the addressable opportunity, which is why the pricing actions in the next section target them.
2. The Pricing Pivot: Trading Price for Volume
In Q3 the company finalized a set of pricing actions for a subset of high-volume benign procedures — cholecystectomy and inguinal hernia repair are the named examples — where cost may constrain access to da Vinci surgery. Two developments drive the quantified outcome:
| Pricing lever | Mechanism | Timing |
|---|---|---|
| Extended-use program 2.0 | Extends useful lives of a subset of core endo-wrist instruments on 4th/5th-gen platforms and introduces volume-based pricing; U.S. rollout requires a 510(k) now in process | By country beginning H1 2027 — U.S. later in Q1 2027 pending clearance, Europe in H2 2027 |
| China charge-code policy | Policy-driven reduction in I&A prices; provincial implementation ongoing alongside green-channel progress for SP and da Vinci 5 | Takes effect in Q4, starting November |
Together, management expects these to lower da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix-constant basis once fully implemented — deliberately isolated from mix effects, and less than the 7% estimated when the first extended-use program launched in 2020. The Q&A added three discipline points: the gross-margin impact will be “modest” and offset across 2027 by cost-reduction programs; elasticity is the explicit intention, with the benefit for high-volume benign procedures “quite a bit greater than the blended” figure, supported by 2020 program data; and the full impact will not arrive until the end of 2027. Accentuating offsets were flagged but excluded from the estimate: force-feedback adoption, the mix shift toward da Vinci 5 and SP (SP I&A per procedure runs above multi-port and is growing faster), and integrated insufflation — used in about 85% of da Vinci 5 cases — which adds roughly $100 per procedure in tube sets. Force feedback itself was used in about 8% of da Vinci 5 cases this quarter, a penetration management wants “quite a bit higher.”
Against this backdrop, da Vinci I&A revenue per procedure was approximately $1,860, up from $1,800 a year ago, driven by higher SP procedures and da Vinci 5-specific I&A. The strategic logic, per the CEO: broader adoption creates more long-term value than near-term revenue per procedure, while innovation on da Vinci 5 continues to be priced in correlation with the value it creates — “it’s not a trade-off.”
3. Capital Performance: Platforms, Geographies, and the ASC Push
| Placements | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Da Vinci 5 | 315 | — | — |
| Xi | 87 | — | — |
| XiR | 65 | — | — |
| SP | 42 | — | — |
| X | 37 | — | — |
| Total da Vinci | 546 | 427 | +28% |
| U.S. | 335 | 263 | +27% |
| OUS | 211 | 164 | +29% |
| — Europe | 115 | 63 | +83% |
| — Asia | 78 | 60 | +30% |
| — Rest of world | 18 | 41 | −56% |
| Ion | 56 | 50 | +12% |
Da Vinci 5 and SP accounted for 65% of global placements, and the company now has more than 2,000 da Vinci 5 systems installed, used by over 18,000 surgeons since launch. Non-U.S. da Vinci 5 placements of 41 (from 12 last year) show the platform internationalizing. U.S. strength was driven by multi-system deals as customers convert to da Vinci 5 — U.S. net placements rose 41%, a change from recent quarters. Europe’s 83% surge included records in Portugal, Turkey, and Austria; the company has recently entered Croatia, Peru, Morocco, and Lithuania and plans to accelerate expansion into unserved countries in 2027. Outside the U.S., nearly 4,000 customers run da Vinci programs and about 25% operate two or more systems; Germany led Europe with 20 installations. A significant new I&A manufacturing facility in Penang, Malaysia begins operations in 2028.
Purchased ASPs demonstrate the tiering strategy: X systems at approximately $500,000 and XiR at approximately $1.2 million, with the average da Vinci selling price around $1.6 million, flat YoY as a higher da Vinci 5 mix was offset by higher XiR mix. On the ASC front, the 18 U.S. ASC installations (15 XiR) are an early-stage, multi-year effort with a deliberately tempered cadence; management sizes ASCs today at a little under 10% of U.S. soft-tissue surgery, with about 70% of those volumes affiliated with existing IDNs — known customers, low penetration. SP placements set a record at 42 (21 U.S., 12 Korea), and the 487-system installed base grew 42%.
4. Financial Results
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Revenue | just over $3.0B, +22% | 84% recurring |
| Instruments & accessories revenue | $1.8B, +18% | per-procedure ~$1,860 vs ~$1,800 |
| Systems revenue | $769M, +30% | — |
| Service revenue | $482M, +22% | — |
| Non-GAAP gross margin | 69.9% | 68.9% ex-$28M IEEPA tariff refund, +90 bps |
| Non-GAAP operating margin | 42% | 41% ex-refund |
| Non-GAAP operating expenses | +18% | variable comp, headcount, prototypes |
| Non-GAAP other income | $75M | vs $83M last quarter, on lower cash after buybacks |
| Non-GAAP effective tax rate | 21.4% | in line with expectations |
| Non-GAAP EPS | $3.00, +25% | — |
| GAAP net income | $523M / $1.49 per share | vs $704M / $1.95, incl. $450M settlement |
| Cash and investments | $6.8B | down from $8.6B last quarter |
| Stock repurchases | $2.9B | at an average $377 per share |
| Capital expenditures | $113M | — |
R&D again grew faster than SG&A, a trend management expects to continue, and the quarter’s $28 million tariff refund was a one-time IEEPA benefit. The $2.9 billion buyback — among the company’s largest — drove the sequential cash decline and is the primary reason full-year other-income guidance was lowered (see the guidance table).
5. Clinical Evidence: The Benign COMPARE Study
Published last month in Annals of Surgery Open by Dr. Thomas Shin and colleagues (Mass General Brigham and the University of Virginia) with Intuitive researchers, Benign COMPARE is a systematic review and meta-analysis of perioperative outcomes in benign surgery — the counterpart to the 2024 oncologic COMPARE study. Its scale: 366 studies across 32 countries published between 2010 and 2024, covering roughly 1.5 million da Vinci patients, 10.7 million laparoscopic patients, and 1.7 million open patients across 13 high-volume benign procedures in general surgery, gynecology, urology, and bariatrics.
Key findings versus laparoscopy:
- 54% lower odds of conversion to open surgery — the most clinically important and consistent finding, significant in benign hysterectomy, ventral and inguinal hernia repair, myomectomy, cholecystectomy, and benign colon surgery.
- 13% lower odds of blood transfusion, plus shorter length of stay, with the largest reductions in benign colon surgery, adrenalectomy, and benign hysterectomy.
- Comparable 30-day complications, readmissions, and mortality; operative times averaged about 24 minutes longer.
Versus open surgery, da Vinci showed larger differences across nearly every measure, including 46% lower odds of postoperative complications and hospital stays nearly two days shorter. The authors concluded da Vinci was associated with fewer conversions, less pain, and faster recovery. This is the clinical substrate beneath the pricing pivot: conversion avoidance and recovery economics are the value story hospitals weigh when the robot competes against entrenched laparoscopy in high-volume benign procedures.
6. Innovation Pipeline and Regulatory Progress
The quarter’s clearance cadence was unusually dense:
- FDA 510(k) clearances: da Vinci 5 surgeon-initiated tool eject and multi-arm targeting (surgeon-reported to extend access beyond traditional workday hours); an integrated version of the da Vinci 5 handheld endoscope (received last week); and, in August, a foundational non-commercial next-generation flexible robotic endoscope for the gastrointestinal tract — an early-stage program marking entry into GI.
- Submitted: a cavitation ultrasonic aspirator instrument for liver and pancreas procedures.
- CE marks: force-feedback instrumentation and cardiac procedures on da Vinci 5, and transvaginal gynecological procedures on SP. Da Vinci 5 is now cleared for cardiac in the U.S., Europe, India, Japan, and Korea.
- Planned: a U.S. submission for the SP vessel sealer in Q4, described as a key enabler for wider SP adoption.
On digital and AI, telepresence adoption keeps increasing and serves as the foundation for telesurgery, where several regulatory clearances are expected in the first half of 2028; a voice-activated user interface and automated fourth-arm control are in development. Management was careful to sequence expectations: AI-controlled motion in surgery “is early and must earn the confidence of regulators, surgeons, care teams, and patients” before deployment at scale.
7. Litigation Settlement
Intuitive reached a no-fault settlement, subject to court approval, with U.S. customers in the class-action lawsuit over third-party remanufacturing of da Vinci instruments and third-party servicing of da Vinci systems. The $450 million charge is reflected in GAAP results, with the court decision not expected until next year. Management’s framing — certainty for both customers and the company, a defined framework for working with third-party remanufacturers and service providers, and preservation of Intuitive’s ability to advance the safety, quality, and security of its products — positions the settlement as a cleanup cost rather than an operating concession. Notably, management offered no quantification of what impact third-party activity had actually had on the business.
8. Updated FY2026 Guidance
| Guidance item | New (October) | Prior (July) |
|---|---|---|
| Da Vinci procedure growth | 14%–15%, closer to midpoint | 13.5%–15.5%, closer to midpoint |
| Non-GAAP gross margin | 68.7%–69.3% | 68%–69% |
| Tariff impact embedded in gross margin | ~90 bps | ~100 bps |
| Non-GAAP operating expense growth | 11%–13% | 11%–13% |
| Non-cash stock compensation | $860M–$870M | — |
| Non-GAAP other income | $300M–$310M | — |
| Q4 non-GAAP effective tax rate | 22% ±50 bps | — |
The gross-margin raise reflects faster growth of newer products (da Vinci 5 and Ion), partially offset by product cost reductions, with continued higher input costs in areas like freight and semiconductor memory. The other-income reduction is driven primarily by Q3 share-repurchase activity. The procedure range continues to consider ACA premium-subsidy changes on U.S. patient behavior and tender volumes and competitive intensity in China.
Conclusion
This was a quarter that beat on every operating line while management deliberately sharpened the knife against its own pricing: the 3–5% per-procedure headwind is the admission price for the benign-procedure volume that international data (41% OUS benign growth, accelerating three quarters running) suggests is real. The tension for investors is between the durability of the installed-base model — record placements, a deepening da Vinci 5 footprint, elasticity evidence from 2020 — and a U.S. procedure print that, however explainable by comps, keeps the burden of proof on 2027. The settlement removes a legal overhang at a manageable cost, and the guidance raise signals confidence without complacency. What happens next is less about Q4 than about January: the long-term opportunity update, the 2027 pricing rollout, and management’s choice between margin defense and investment will frame the stock’s next leg.
Artifacts and Follow-Ups
Key Artifacts — highest priority
- EUP 2.0 U.S. clearance and rollout. The linchpin of the pricing strategy’s timing: the 510(k) is in process with U.S. rollout expected later in Q1 2027, Europe in H2 2027, and full 3–5% impact only at end-2027. A clearance slip pushes the entire revenue-per-procedure bridge right.
- China charge-code implementation from November. The first live test of the pricing plan, beginning in Q4 against a baseline of ~$1,860 da Vinci I&A revenue per procedure; watch provincial execution, green-channel progress for da Vinci 5 and SP, and any customer stocking.
- U.S. procedure growth against the policy overhang. Q3’s 10% U.S. da Vinci growth came against the year’s hardest comparison; the FY guide of 14%–15% (closer to midpoint) now has to be carried by Q4 with ACA enrollment, Medicaid eligibility, and 340B all live variables.
- The January 2027 guidance event. Management committed to updating its estimate of the long-term soft-tissue opportunity, accelerating expansion into new countries, and giving 2027 expense guidance after signaling it has “capacity to invest” the 41–42% operating margin against a 35–40% long-term range.
- SP vessel sealer U.S. submission in Q4. Management called it a key enabler for wider SP adoption; the submission (and subsequent clearance path) gates the next leg of the SP story, which is growing procedures at 55%.
Secondary Tracking Items
- ASC placement cadence after 18 U.S. installs this quarter, and whether XiR supply keeps pace with demand.
- Ion reimbursement actions in additional geographies following Korea.
- Force-feedback penetration of da Vinci 5 cases (8% this quarter) and the evidence build behind it.
- Buyback pace after $2.9 billion in Q3 and its effect on other income.
- ROSE on-site cytology and integrated endobronchial ultrasound milestones on Ion — management flagged both as accretive to revenue per case.
- Cardiac and breast procedure growth off small bases, and training/evidence accumulation in both.